Skip to main content

Table 1 Clinical-pathological correlations for TYMS gene expression in NSCLC patients treated with pemetrexed

From: Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer

   Total TYMS high expression TYMS low expression  
   n n % n % P-value
Age (mean (range))   57 (32–79) 54 (32–79)   66 (60–78)   1
Gender Male 40 26 65.0 14 35.0 0.419
Female 22 12 54.5 10 45.5  
Smoking habit Current smoker 24 18 75.0 6 25.0 0.056
Former smoker 22 14 63.6 8 36.4  
Never smoker 16 6 37.5 10 62.5  
Histology Adenocarcinoma 49 27 55.1 22 44.9 0.071
NSCLC nos 7 7 100 0 0  
Squamous cell carcinoma 6 4 66.7 2 33.3  
ECOG performance status ECOG0 27 19 70.4 8 29.6 0.392
ECOG1 32 17 53.1 15 46.9  
ECOG2 3 2 66.7 1 33.3  
Line of treatment 1st line 16 9 56.3 7 43.8 0.661
2nd line 14 10 71.4 4 28.6  
3rd, further lines 32 19 59.4 13 40.6  
Response No 45 30 66.7 15 33.3 0.025
Yes 7 1 14.3 6 85.7  
Not evaluatable 10 7 70.0 3 30.0  
Progression No 24 4 16.7 20 83.3 0.003
Yes 38 34 89.5 4 10.5